Catalyst
Slingshot members are tracking this event:
Halozyme Therapeutics (HALO) to commence Phase 1b/2 open label trial—under MORPHEUS platform—on PEG PH20, testing six tumors, including gastrointestinal, in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HALO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Occurred Source:
http://www.halozyme.com/investors/news-releases/news-release-details/2017/Initiation-Of-Clinical-Trial-Collaboration-Evaluating-Halozymes-PEGPH20-In-Combination-With-Anti-PDL1-Immunotherapy/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Morpheus, Gastrointestinal Cancer, Tumors, Pegph20, Phase 1b/2
